We can’t show the full text here under this license. Use the link below to read it at the source.
Effect of once‐weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial
Once-weekly exenatide’s impact on kidney function changes varies with starting kidney risk
AI simplified
Abstract
In a study of 3,503 participants, once-weekly exenatide significantly improved (eGFR) slope in those with elevated baseline (UACR).
- Exenatide improved eGFR slope by 0.79 mL/min/1.73 m/year in participants with baseline UACR >100 mg/g and by 1.32 mL/min/1.73 m/year in those with UACR >200 mg/g compared to placebo.
- No significant improvement in eGFR slope was observed in participants with lower baseline UACR levels.
- Exenatide also reduced UACR by 28.2% in participants with baseline UACR >30 mg/g, 22.5% in those with UACR >100 mg/g, and 34.5% in those with UACR >200 mg/g.
- The findings suggest potential benefits of exenatide in managing renal function in patients with type 2 diabetes at high risk of renal function loss.
AI simplified
Key numbers
0.79 mL/min/1.73 m/year
Increase in Slope
Compared to placebo in participants with baseline >100 mg/g
28.2%
Reduction in
In participants with baseline >30 mg/g
34.5%
Further Reduction in
In participants with baseline >200 mg/g